Abstract
The uptake and utilization of glucose and glutamine by cancer cells are markedly higher than by most nontransformed, normal epithelial and mesenchymal cells. This metabolic shift enables the production of ATP and anabolic precursors necessary for the synthesis of proteins, lipids and nucleotides required for survival, proliferation and invasiveness. The observations that certain oncogenic proteins (Ras, c-Myc and HIF-1) and tumor suppressors (p53, PTEN, Rb and VHL) regulate the expression and activity of several metabolic enzymes have supported their potential as molecular targets for the development of anti-neoplastic agents. Indeed, recent pre-clinical studies have shown that several established and novel inhibitors of metabolic enzymes exhibit reasonable therapeutic indices when tested in xenograft models of tumorigenesis. In this review, we will discuss the rationale of targeting metabolic enzymes for the treatment of cancer and then will describe published pre-clinical and clinical data for several inhibitors of metabolism in cancer.
Keywords: Glycolysis, chemotherapy, glucose.
Current Enzyme Inhibition
Title:Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
Volume: 9 Issue: 2
Author(s): Julie O’Neal and Jason Chesney
Affiliation:
Keywords: Glycolysis, chemotherapy, glucose.
Abstract: The uptake and utilization of glucose and glutamine by cancer cells are markedly higher than by most nontransformed, normal epithelial and mesenchymal cells. This metabolic shift enables the production of ATP and anabolic precursors necessary for the synthesis of proteins, lipids and nucleotides required for survival, proliferation and invasiveness. The observations that certain oncogenic proteins (Ras, c-Myc and HIF-1) and tumor suppressors (p53, PTEN, Rb and VHL) regulate the expression and activity of several metabolic enzymes have supported their potential as molecular targets for the development of anti-neoplastic agents. Indeed, recent pre-clinical studies have shown that several established and novel inhibitors of metabolic enzymes exhibit reasonable therapeutic indices when tested in xenograft models of tumorigenesis. In this review, we will discuss the rationale of targeting metabolic enzymes for the treatment of cancer and then will describe published pre-clinical and clinical data for several inhibitors of metabolism in cancer.
Export Options
About this article
Cite this article as:
O’Neal Julie and Chesney Jason, Targeting Metabolic Enzymes in Cancer – Clinical Trials Update, Current Enzyme Inhibition 2013; 9 (2) . https://dx.doi.org/10.2174/1573408011309020007
DOI https://dx.doi.org/10.2174/1573408011309020007 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Increased Risk of Cardiovascular Complications in Chronic Kidney Disease: A Possible Role of Leptin
Current Pharmaceutical Design Helicobacter Pylori Infection, Immune Response and Vaccination
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Protrhombotic Effects of Contraceptives
Current Pharmaceutical Design Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects
Cardiovascular & Hematological Disorders-Drug Targets Virgin Olive Oil and Hypertension
Current Vascular Pharmacology Understanding Respiratory Syncytial Virus Infection to Improve Treatment and Immunity
Current Molecular Medicine Obesity-Driven Inflammation and Colorectal Cancer
Current Medicinal Chemistry Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
Current Nutraceuticals Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Cardioprotection by Regular Ethanol Consumption: Potential Mechanisms and Clinical Application
Current Drug Abuse Reviews Uric Acid and Diabetes: Is there a Link?
Current Pharmaceutical Design Anticoagulant Therapy During Pregnancy for Maternal and Fetal Acquired and Inherited Thrombophilia
Current Medicinal Chemistry TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters Atherosclerosis is an Inflammatory Disorder After All
Current Topics in Medicinal Chemistry Recent Advances in the Discovery and Development of Direct Coagulation Factor Xa Inhibitors
Current Pharmaceutical Design